CognitiveNot FDA ApprovedClinical Trials

Normoftal

Also known as Eye Peptide Bioregulator, Retina Peptide, AKS-G Peptide

Synthesized Khavinson peptide bioregulator containing short peptides (2-4 amino acids) derived from retinal tissue. 1,500 patients treated from 1995-2010 with 95% showing improved visual functions.

Approved in Russia - Clinical use for retinal support

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

20-40 mg daily (therapy); 20 mg daily (prevention)

Frequency

1-2x daily, before meals

Duration

30-day courses, repeat after 2-6 months

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 20-40 mg daily (therapy); 20 mg daily (prevention) via Oral capsules, before meals, 1-2x daily, before meals. Dose range: 20-40 mg daily. Duration: 30-day courses, repeat after 2-6 months.

Timing & Administration

Administer via Oral capsules, before meals. Frequency: 1-2x daily, before meals.

Mechanism of Action

Reduces peptide deficiency and restores protein synthesis in retinal cells. Contains peptide AKS-G (lysine, glutamic acid). Provides neuroprotective effects through modulation of gene expression and protein synthesis.

Research Summary

Evidence level: clinical trials. Clinical status: Approved in Russia - Clinical use for retinal support.

Side Effects & Safety

Important Warnings

  • Should not replace standard eye treatments
Well-tolerated with no reported adverse reactions
individual intolerance to components (rare)

References

No references available.